Nov 13, 2025
CTOS 2025 Annual Meeting – EFTISARC-NEO trial with neoadjuvant eftilagimod alfa (Soft Tissue Sarcoma)
Oct 29, 2025
Immutep Corporate Presentation
Oct 19, 2025
ESMO Congress 2025 – EFTISARC-NEO (Soft Tissue Sarcoma)
Oct 18, 2025
ESMO Congress 2025 – INSIGHT-003 (First Line Non-Small Cell Lung Cancer)
ESMO Congress 2025 – TACTI-004 (First Line Non-Small Cell Lung Cancer)
Dec 12, 2024
ESMO Immuno-Oncology 2024 – TACTI-003, Cohort B (Metastatic Head and Neck Squamous Cell Carcinoma)
Nov 22, 2024
2024 AGM CEO Presentation
Nov 13, 2024
CTOS 2024 Annual Meeting – EFTISARC-NEO trial of neoadjuvant soluble LAG-3 protein (Soft Tissue Sarcoma)
Sep 15, 2024
ESMO Congress 2024 – TACTI-003, Cohort A (Head and Neck Squamous Cell Carcinoma)
Jul 12, 2024
ESMO Virtual Plenary 2024 – TACTI-003, Cohort B (Head and Neck Squamous Cell Carcinoma)
Jul 11, 2024
Global Webcast Slides for TACTI-003 Positive Data in Patients with Negative PD-L1 Expression (Cohort B)
Jun 26, 2024
Immutep Global Webcast Slides for New Efti Clinical Data in 1st Line HNSCC
